duchenne muscular dystrophy

FDA Approves Duchenne Muscular Dystrophy Drug

Scientists in Australia had originally developed Eteplirsen®, a drug that treats a rare and fatal muscle-wasting disease affecting one in 3,500 boys worldwide.

Perfecting Gene Editing For DMD On iPS Cells

By combining iPS and gene editing technology, correcting the mutation in Duchenne muscular dystrophy patients has been made more precise.

Duchenne Muscular Dystrophy Drug Completes Phase II Trial

An Australian-developed compound for the treatment of Duchenne Muscular Dystrophy has undergone a Phase II study in the U.K.